Actual position of metformin in the treatment of type 2 diabetes mellitus

Česká verzia

Authors: Peter Galajda; Martin Jozef Péč; Simona Horná; Marián Mokáň
Authors place of work: I. interná klinika JLF UK a UNM, Martin
Published in the journal: Forum Diab 2024; 13(2): 90-95
Category: Review Article

Summary

According to actual algorithm of treatment of type 2 diabetic patients metformin is indicated as drug of first choice only in patients with low cardiovascular risk. However metformin has potential cardioprotective and nephroprotective effects, and it is important drug due to its mechanism of action. Activation of AMPK system by metformin is associated not only with improving of insulin sensitivity, but also with various extraglycemic effects such as beneficial remodelling of fat tissue with reducing of visceral and ectopic adiposity and induction of brown adipose tissue, reduction of systemic and local inflammatory reaction a antiatherothrombotic effects. Metformin has important anti-inflammatory and anticancer effect as well as preventive effect on origin of type 2 diabetes mellitus.

Keywords:

type 2 diabetes mellitus – cardiovascular benefit – anticancer effect – prediabetic states – type 2 diabetes preven-tion

Zdroje

Ndumele CE, Neeland IJ, Tuttle KR et al. [American Heart Association]. A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: A scientific statement from the American Heart Association. Circulation 2023; 148(20): 1636–1664. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000001186>.

[American Diabetes Association]. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024. Diabetes Care 2024; 47(Suppl 1): S158–S178. Dostupné z DOI: <http://dx.doi.org/10.2337/dc24-S009>.

Bailey CJ. Metformin: historical overview. Diabetologia 2017; 60(9): 1566–1576. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–017–4318-z>.

[UK Prospective Diabetes Study (UKPDS) Group]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–853. Dostupné z DOI: <https://doi.org/10.1016/S0140–6736(98)07019–6>.

[UK Prospective Diabetes Study (UKPDS) Group]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–865. Erratum in Lancet 1998; 352(9139): 1558. Dostupné z DOI: <https://doi.org/10.1016/S0140–6736(98)07037–8>.

[UK Prospective Diabetes Study Group]. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703–713. Dostupné z DOI: <https://doi.org/ 10.1136/bmj.317.7160.703>.

Kooy A, de Jager J, Lehert P et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169(6): 616–625. Dostupné z DOI: <http://dx.doi.org/10.1001/archinternmed.2009.20>.

Hong J, Zhang Y, Lai S et al. SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013; 36(5): 1304–1311. Dostupné z DOI: <http://dx.doi.org/10.2337/dc12–0719>.

Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 2017; 60(9): 1620–1629. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–017–4337–9>.

Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577–1589. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0806470>.

Martinka E, Tkáč I, Mokáň M et al. Odporúčané postupy pre liečbu diabetes mellitus 2. typu – 2023. Forum Diab 2023; 12(2): 93–133.

Ravindran S, Kuruvilla V, Wilbur K et al. Nephroprotective effects of metformin in diabetic nephropathy. J Cell Physiol 2017; 232(4): 731–742. Dostupné z DOI: <http://dx.doi.org/10.1002/jcp.25598>.

De Broe ME, Kajbaf F, Lalau J-D. Renoprotective effects of metformin. Nephron 2018; 138(4): 261–274. Dostupné z DOI: <http://dx.doi.org/10.1159/000481951>.

Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol (Lausanne) 2020; 11: 191. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2020.00191>.

Giaccari A, Solini A, Frontoni S et al. Metformin benefits: Another example for alternative energy substrate mechanism? Diabetes Care 2021; 44(3): 647–654. Dostupné z DOI: <http://dx.doi.org/10.2337/dc20–1964>.

Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ 2016; 352: i1450. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.i1450>.

Kwon S, Kim YC, Park JY et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020; 43(5): 948–955. Dostupné z DOI: <http://dx.doi.org/10.2337/dc19–0936>.

Kawanami D, Takashi Y, Tanabe M. Significance of metformin use in diabetic kidney disease. Int J Mol Sci 2020; 21(12): 4239. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms21124239>.

Petrie JR, Rossing PR, Campbell IW. Metformin and cardiorenal outcomes in diabetes: A reappraisal. Diabetes Obes Metab 2020; 22(6): 904–915. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.13984>.

Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia 2017; 60(9): 1577–1585. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–017–4342-z>.

Kyriachenko Y, Falalyeyeva T, Korotkyi O et al. Crosstalk between gut microbiota and antidiabetic drug action. World J Diabetes 2019; 10(3): 154–168. Dostupné z DOI: <http://dx.doi.org/10.4239/wjd.v10.i3.154>.

Cao TTB, Wu KC, Hsu JL et al. Effects of non-insulin anti-hyperglycemic agents on gut microbiota: A systematic review on human and animal studies. Front Endocrinol (Lausanne) 2020; 11: 573891. Dostupné z DOI: <http://dx.doi.org/10.3389/fendo.2020.573891>.

Galajda P, Mokáň M. Metabolický syndróm, diabetes mellitus a pridružené ochorenia. QuickPrint: Martin 2020. ISBN 978– 80–972594–6–4.

Feng YY, Wang Z, Pang H. Role of metformin in inflammation. Mol Biol Rep 2023; 50(1): 789–798. Dostupné z DOI: <http://dx.doi.org/10.1007/s11033–022–07954–5>.

Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol 2023; 19(8): 460–476. Dostupné z DOI: <http://dx.doi.org/10.1038/s41574–023–00833–4>.

Luo P, Qiu L, Liu Y et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg 2020; 103(1): 69–72. Dostupné z DOI: <http://dx.doi.org/10.4269/ajtmh.20–0375>.

Bramante CT, Buse J, Tamaritz L et al. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. J Med Virol 2021; 93(7): 4273–4279. Dostupné z DOI: <http://dx.doi.org/10.1002/jmv.26873>.

Jiang N, Chen Z, Liu L et al. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study. Diabetes Res Clin Pract 2021; 173: 108619. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2020.108619>.

Naseri A, Sanaie S, Hamzehzadeh S et al. Metformin: new applications for an old drug. J Basic Clin Physiol Pharmacol 2022; 34(2): 151–160. Dostupné z DOI: <http://dx.doi.org/10.1515/jbcpp-2022–0252>.

Marini C, Cossu V, Bauckneht M et al. Metformin and cancer glucose metabolism: At the bench or at the bedside? Biomolecules 2021; 11(8): 1231. Dostupné z DOI: <http://dx.doi.org/10.3390/biom11081231>.

Monami M, Colombi C, Balzi D et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011; 34(1): 129–131. Dostupné z DOI: <http://dx.doi.org/10.2337/dc10–1287>.

Galajda P, Mokáň Mi, Michalovičová M et al. Nádorové ochorenia a poruchy metabolizmu glukózy. Quick Print: Martin 2014. ISBN 9788097096922.

Farmer RE, Ford D, Forbes HJ et al. Metformin and cancer in type 2 diabetes: A systematic review and comprehensive bias evaluation. Int J Epidemiol 2017; 46(2): 728–744. Dostupné z DOI: <http://dx.doi.org/10.1093/ije/dyw275>.

Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV et al. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 2017; 60: 1639–1647. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–017–4372–6>.

Ng CW, Jiang AA, Toh EMS et al. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. Int J Colorectal Dis 2020; 35(8): 1501–1512. Dostupné z DOI: <http://dx.doi.org/10.1007/s00384–020–03676-x>.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393–403. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa012512>.

Zhang L, Zhang Y, Shen S et al. [China Diabetes Prevention Program Study Group]. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2023; 11(8): 567–577. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(23)00132–8>.

American Diabetes Association. Prevention or delay of diabetes and associated comorbidities. Standards of care in diabetes – 2024. Diabetes Care 2024; 47 (Supplement 1): S43-S51. Dostupné z DOI: <http://dx.doi.org/10.2337/dc24-S003>.